Correlation of baseline ENPP1 and cGAS expression in advanced solid tumors with intratumoral immune activation and clinical outcomes after treatment with the first-in-class oral ENPP1 inhibitor RBS2418, alone or in combination with pembrolizumab.
Thomas U. Marron(Icahn School of Medicine at Mount Sinai), Jamal Misleh(Christiana Care Health System), Jennifer Segar(University of Arizona), Alexander I. Spira(Virginia Cancer Specialists), Ningwu Huang(University of California, San Francisco), Klaus Klumpp(Veroscience (United States)), Ildiko Csiki(Veroscience (United States)), Christopher T. Chen(Cancer Institute (WIA)), Jeffrey Glen(Stanford Medicine), Michael S. Gordon(HonorHealth), Juergen Schanzer(Veroscience (United States)), Zev A. Wainberg(University of California, Los Angeles), Ralph V. Boccia(Center for Cancer and Blood Disorders), Jordan Berlin(Dana-Farber Cancer Institute)
Cited by 3
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761